公开(公告)号：US20240052016A1

公开(公告)日：2024-02-15

申请号：US18494508

申请日：2023-10-25

Applicant: EpicentRX, Inc.

Inventor： Christopher LARSON ,  Tony R. Reid ,  Bryn T. Oronsky

IPC: C07K14/715 ,  A61P35/00 ,  C07K14/54 ,  C12N15/62

CPC classification number: C07K14/7155 ,  A61P35/00 ,  C07K14/5428 ,  C12N15/62 ,  A61K38/00

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20210139560A1

公开(公告)日：2021-05-13

申请号：US17150993

申请日：2021-01-15

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Tony R. REID ,  Bryan T. ORONSKY

IPC: C07K14/71 ,  C12N7/00 ,  A61P35/00 ,  C07K16/00 ,  C12N15/86

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20180369404A1

公开(公告)日：2018-12-27

申请号：US15991745

申请日：2018-05-29

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan ORONSKY ,  Tony R. REID

IPC: A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  A61K47/69 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N7/04

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US20240294883A1

公开(公告)日：2024-09-05

申请号：US18649467

申请日：2024-04-29

Applicant: EpicentRx, Inc.

Inventor： Tony R. REID ,  Bryan T. ORONSKY ,  Christopher LARSON

IPC: C12N7/00

CPC classification number: C12N7/00 ,  C12N2710/10321 ,  C12N2710/10322 ,  C12N2710/10332 ,  C12N2710/10352

Abstract: The present disclosure relates to compositions and methods for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

公开(公告)号：US20220125946A1

公开(公告)日：2022-04-28

申请号：US17575488

申请日：2022-01-13

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan ORONSKY ,  Tony R. REID

IPC: A61K47/68 ,  C12N15/85 ,  A61P35/00 ,  A61K47/69 ,  C12N7/04 ,  A61K48/00 ,  C12N15/62 ,  C12N7/02 ,  C12N15/86

Abstract: Disclosed herein are recombinant adenoviruses with one or more nucleotide sequences inserted between two viral transcription units, formulations comprising the recombinant adenoviruses, and methods of treatment using the recombinant adenoviruses. In some embodiments, the one or more nucleotide sequences are inserted in an IX-E2 insertion site and/or an L5-E4 insertion site.

公开(公告)号：US20250074967A1

公开(公告)日：2025-03-06

申请号：US18772025

申请日：2024-07-12

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Tony R. REID ,  Bryan T. ORONSKY

IPC: C07K14/71 ,  A61K35/768 ,  A61K38/00 ,  A61K48/00 ,  A61P35/00 ,  C07K16/00 ,  C12N7/00 ,  C12N15/86

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

公开(公告)号：US20210015878A1

公开(公告)日：2021-01-21

申请号：US17042822

申请日：2019-03-28

Applicant: EpicentRx, Inc.

Inventor： Christopher LARSON ,  Bryan T. ORONSKY ,  Tony R. REID

IPC: A61K35/761 ,  A61K38/16 ,  C12N15/10 ,  C12N15/861

Abstract: The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.